Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

IMGN901

Home/Tag:IMGN901
8 06, 2011

More ASCO News, Along With A Short, Personal Medical Update

Tags: , , , , , , , , , , |2 Comments

Let's jump right in with more ASCO news. Of course, there were lots of study results featuring new drugs used in combination with Revlimid and Velcade.  As you should have noticed by now, the combination approach is the new "in thing" when treating myeloma.  The Revlimid/Velcade/dexamethasone (RVD) induction combination I'm enduring now, prior to my stem

18 11, 2010

ImmunoGen, Inc To Present At American Society Of Hematology Meetings (ASH) In Orlando In Two Weeks

Tags: , , , |2 Comments

Here is another pre-ASH press release from a drug company, ImmunoGen, I found posted on Marketwatch.com yesterday:Nov. 17, 2010ImmunoGen, Inc. Announces Clinical Data Presentations at the 52nd ASH Annual Meeting and Exposition WALTHAM, Mass., Nov 17, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that three presentations of

14 12, 2009

MMRF’s Review Of Novel Therapy News From ASH

Tags: , , , , , , , , |0 Comments

Here is a copy of the MMRF's review of novel therapy news from ASH last week:Novel drugs Data from two investigational trials of pomalidomide in relapsed or refractory myeloma patients after treatment with Revlimid or Revimid and bortezomib was presented at the meeting. Results from an ongoing Phase II study showed promising overall response rates